Compare Adaptive Biotechnologies Corp (ADPT) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Monolithic Power Systems Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.2 (market cap $4.02B), while Monolithic Power Systems Inc trades at $1,420.57 (market cap $70.03B). The key difference: Monolithic Power Systems Inc is far larger — about 17.4× Adaptive Biotechnologies Corp's market cap, and Monolithic Power Systems Inc pays a 0.56% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MPWR | |
|---|---|---|
Market Cap | $4.02B | $70.03B |
Sector | Health | Utilities |
52-Week High | $25.45 | $1.69K |
52-Week Low | $12.30 | $820.74 |
Enterprise Value | $4.08B | $68.63B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
MPWR trades at $1,425.01, up 3.18% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 24.5% net income margin and 21.98% ROE, supported by AI-driven revenue growth. Recent news highlights legal scrutiny but also analyst optimism post-Q2 results.
Outlook is positive with an 88% buy rating from analysts and a $1,870 consensus price target, though high valuation ratios and competitive risks warrant caution. Upside hinges on continued AI infrastructure demand, while downside risks include execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
